Q-omics provides the consensus-scored PLEKHG1 profile across patient tissues and cancer cell-line models. PLEKHG1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLEKHG1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PLEKHG1 protein abundance shows 20,041 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where PLEKHG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHG1 survival associations across molecular data types. PLEKHG1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHG1 RNA expression–survival associations across cancer types. High PLEKHG1 expression shows unfavorable associations in KIRP, LGG and UVM, but favorable associations in KIRC, LUAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLEKHG1 RNA expression.
This table summarizes PLEKHG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHG1 shows lower tumor expression in KICH, LUSC and BRCA and higher tumor expression in STAD, THCA and KIRC. The KICH box plot shows higher PLEKHG1 RNA expression in normal versus tumor tissue (log2 FC = −2.277, t-test p < 0.001).
This table shows molecular features associated with PLEKHG1 in patient tissues and cancer cell lines. In patient samples, PLEKHG1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
